1. Home
  2. AEG vs ABVX Comparison

AEG vs ABVX Comparison

Compare AEG & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEG

Aegon Ltd. New York Registry Shares

HOLD

Current Price

$6.80

Market Cap

11.1B

Sector

Finance

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$120.63

Market Cap

9.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEG
ABVX
Founded
1983
2013
Country
Netherlands
France
Employees
15500
67
Industry
Life Insurance
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
11.1B
9.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AEG
ABVX
Price
$6.80
$120.63
Analyst Decision
Hold
Buy
Analyst Count
1
13
Target Price
N/A
$130.85
AVG Volume (30 Days)
5.6M
743.8K
Earning Date
02-09-2023
03-23-2026
Dividend Yield
5.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$175.15
N/A
Revenue Next Year
$1.22
$0.22
P/E Ratio
$7.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.42
$4.77
52 Week High
$8.15
$148.83

Technical Indicators

Market Signals
Indicator
AEG
ABVX
Relative Strength Index (RSI) 34.85 51.22
Support Level N/A $106.37
Resistance Level $8.02 $131.27
Average True Range (ATR) 0.15 5.07
MACD -0.01 0.90
Stochastic Oscillator 10.31 69.98

Price Performance

Historical Comparison
AEG
ABVX

About AEG Aegon Ltd. New York Registry Shares

Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle funds into capital-light and more predictable strategic businesses.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: